Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07XYT
|
|||
| Former ID |
DCL000164
|
|||
| Drug Name |
Medusa IL-2
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Flamel Technol
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.